Kurt Hertogs
11Patents
6h-index
31Co-inventors
62Inventor score
Filing activity: Jul 24, 1998 → Jan 13, 2009
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US7292944B2 | Establishment of biological cut-off values for predicting resistance to therapy | Physics | 32 | Expired |
| US6221578A | Method of managing the chemotherapy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains | Emerging Cross-Sectional Technologies | 13 | Expired |
| US7206699B2 | Methods for measuring therapy resistance | Physics | 11 | Expired |
| US7442705B2 | HIV replication inhibiting pyrimidines and triazines | Chemistry; Metallurgy | 11 | Expired |
| US7494768B1 | Mutational profiles in HIV-1 protease and reverse transcriptase correlated with phenotypic drug resistance | Emerging Cross-Sectional Technologies | 8 | Expired |
| US6528251B2 | Method of managing the chemotherapy of patients who are HIV positive based on the phenotypic drug sensitivity of human HIV strains | Emerging Cross-Sectional Technologies | 6 | Expired |
| US7585870B2 | HIV replication inhibiting pyrimidines and triazines | Chemistry; Metallurgy | 3 | Expired |
| US8574831B2 | Mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance | Physics | 0 | Active |
| US7429677B2 | Small molecule entry inhibitors | Chemistry; Metallurgy | 0 | Expired |
| US7608726B2 | Substituted indolepyridinium as anti-infective compounds | Human Necessities | 0 | Expired |
| US8563236B2 | Mutational profiles in HIV-1 reverse transcriptase correlated with phenotypic drug resistance | Emerging Cross-Sectional Technologies | 0 | Active |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.